This HTML5 document contains 127 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00795/identifier/pubchem-compound/
n26http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n30http://linked.opendata.cz/resource/mesh/concept/
n6http://linked.opendata.cz/resource/drugbank/company/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00795/identifier/pubchem-substance/
n22http://linked.opendata.cz/resource/drugbank/dosage/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00795/identifier/kegg-drug/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00795/identifier/drugbank/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00795/identifier/national-drug-code-directory/
n13http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n25http://www.rxlist.com/cgi/generic/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00795/identifier/chemspider/
n12http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n18http://linked.opendata.cz/resource/drugbank/drug/DB00795/identifier/chebi/
n29http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n8http://www.drugs.com/cdi/
n4http://linked.opendata.cz/resource/drugbank/property/
n28http://linked.opendata.cz/resource/drugbank/drug/DB00795/identifier/wikipedia/
xsdhhttp://www.w3.org/2001/XMLSchema#
n27http://linked.opendata.cz/resource/drugbank/drug/DB00795/identifier/pharmgkb/
n10http://linked.opendata.cz/resource/atc/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00795/identifier/kegg-compound/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00795/identifier/pdb/
n9http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00795
rdf:type
n3:Drug
n3:description
A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see mesalamine) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
n3:dosage
n22:271B646D-363D-11E5-9242-09173F13E4C5 n22:271B646E-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
5-10 hours
n3:indication
For the treatment of Crohn's disease and rheumatoid arthritis as a second-line agent.
n3:manufacturer
n6:271B645A-363D-11E5-9242-09173F13E4C5 n6:271B6461-363D-11E5-9242-09173F13E4C5 n6:271B645F-363D-11E5-9242-09173F13E4C5 n6:271B6460-363D-11E5-9242-09173F13E4C5 n6:271B645D-363D-11E5-9242-09173F13E4C5 n6:271B645E-363D-11E5-9242-09173F13E4C5 n6:271B645B-363D-11E5-9242-09173F13E4C5 n6:271B645C-363D-11E5-9242-09173F13E4C5
owl:sameAs
n12:DB00795 n13:DB00795
dcterms:title
Sulfasalazine
adms:identifier
n15:C07316 n16:D00448 n17:DB00795 n18:9334 n19:4510284 n20:5359476 n21:46505451 n23:0013-0102-01 n24:SAS n27:PA451547 n28:Sulfasalazine
n3:mechanismOfAction
The mode of action of Sulfasalazine or its metabolites, 5-aminosalicylic acid (5-ASA) and sulfapyridine (SP), is still under investigation, but may be related to the anti-inflammatory and/or immunomodulatory properties that have been observed in animal and <i>in vitro</i> models, to its affinity for connective tissue, and/or to the relatively high concentration it reaches in serous fluids, the liver and intestinal walls, as demonstrated in autoradiographic studies in animals. In ulcerative colitis, clinical studies utilizing rectal administration of Sulfasalazine, SP and 5-ASA have indicated that the major therapeutic action may reside in the 5-ASA moiety. The relative contribution of the parent drug and the major metabolites in rheumatoid arthritis is unknown.
n3:packager
n6:271B6440-363D-11E5-9242-09173F13E4C5 n6:271B6441-363D-11E5-9242-09173F13E4C5 n6:271B643F-363D-11E5-9242-09173F13E4C5 n6:271B6444-363D-11E5-9242-09173F13E4C5 n6:271B6445-363D-11E5-9242-09173F13E4C5 n6:271B6442-363D-11E5-9242-09173F13E4C5 n6:271B6443-363D-11E5-9242-09173F13E4C5 n6:271B6450-363D-11E5-9242-09173F13E4C5 n6:271B6451-363D-11E5-9242-09173F13E4C5 n6:271B644E-363D-11E5-9242-09173F13E4C5 n6:271B644F-363D-11E5-9242-09173F13E4C5 n6:271B6457-363D-11E5-9242-09173F13E4C5 n6:271B6458-363D-11E5-9242-09173F13E4C5 n6:271B6452-363D-11E5-9242-09173F13E4C5 n6:271B6456-363D-11E5-9242-09173F13E4C5 n6:271B6448-363D-11E5-9242-09173F13E4C5 n6:271B6449-363D-11E5-9242-09173F13E4C5 n6:271B6446-363D-11E5-9242-09173F13E4C5 n6:271B6447-363D-11E5-9242-09173F13E4C5 n6:271B644C-363D-11E5-9242-09173F13E4C5 n6:271B644D-363D-11E5-9242-09173F13E4C5 n6:271B644A-363D-11E5-9242-09173F13E4C5 n6:271B644B-363D-11E5-9242-09173F13E4C5 n6:271B6455-363D-11E5-9242-09173F13E4C5 n6:271B6453-363D-11E5-9242-09173F13E4C5 n6:271B6454-363D-11E5-9242-09173F13E4C5 n6:271B6459-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
The majority of 5-ASA stays within the colonic lumen and is excreted as 5-ASA and acetyl-5-ASA with the feces.
n3:synonym
Salicylazosulfapyridine Azulfidine Salazosulfapyridinum Sulfasalazin Sulfasalazinum Azopyrin Salazosulfapiridina Sulfasalazina 4-(Pyridyl-2-amidosulfonyl)-3'-carboxy-4'-hydroxyazobenzene 5-(P-(2-Pyridylsulfamyl)phenylazo)salicylic acid Salazosulfapyridine Sulfasalazine 5-(4-(2-Pyridylsulfamoyl)phenylazo)-2-hydroxybenzoic acid 5-((P-(2-Pyridylsulfamoyl)phenyl)azo)salicylic acid 2-Hydroxy-5-[4-(pyridin-2-ylsulfamoyl)-phenylazo]-benzoic acid 2-Hydroxy-5-((4-((2-pyridinylamino)sulfonyl)phenyl)azo)benzoic acid
n3:volumeOfDistribution
* 7.5 ± 1.6 L
n9:hasAHFSCode
n26:08-12-20
n3:foodInteraction
Take with a full glass of water No iron, zinc or fluoride within 2 hours of taking this medication. May take Vitamin D. Take with food.
n29:hasConcept
n30:M0019365
foaf:page
n8:sulfasalazine.html n25:sulfasal.htm
n3:IUPAC-Name
n4:271B6473-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B6479-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B6478-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B6475-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B6476-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B6477-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B6471-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B648A-363D-11E5-9242-09173F13E4C5 n4:271B646F-363D-11E5-9242-09173F13E4C5 n4:271B6472-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B6470-363D-11E5-9242-09173F13E4C5
n9:hasATCCode
n10:A07EC01
n3:H-Bond-Acceptor-Count
n4:271B647F-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B6480-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B647A-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B647B-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B647D-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B647C-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B647E-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:caco2-Permeability
n4:271B648B-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
599-79-1
n3:category
n3:clearance
* 1 L/h [IV administration]
n3:containedIn
n5:271B6466-363D-11E5-9242-09173F13E4C5 n5:271B6467-363D-11E5-9242-09173F13E4C5 n5:271B6464-363D-11E5-9242-09173F13E4C5 n5:271B6465-363D-11E5-9242-09173F13E4C5 n5:271B6462-363D-11E5-9242-09173F13E4C5 n5:271B6463-363D-11E5-9242-09173F13E4C5 n5:271B646B-363D-11E5-9242-09173F13E4C5 n5:271B646C-363D-11E5-9242-09173F13E4C5 n5:271B646A-363D-11E5-9242-09173F13E4C5 n5:271B6468-363D-11E5-9242-09173F13E4C5 n5:271B6469-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B6485-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B6487-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B6488-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B6489-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B6484-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B6483-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B6486-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B6474-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B6481-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B6482-363D-11E5-9242-09173F13E4C5